Adenoviral vector-based strategies for cancer therapy.
Adenoviral vector-based strategies for cancer therapy.
复制标题
DOI：
10.2174/157488509788185123
复制
发表时间：
2009-05-01
影响因子：
0.6
通讯作者：
Mittal SK
中科院分区：
文献类型：
--
作者：
Sharma A;Tandon M;Bangari DS;Mittal SK
几十年来，科学家们一直未能找到癌症的有效治疗方法。目前的治疗方式如手术、化疗、放疗和受体靶向抗体具有不同程度的成功，并且通常具有中度至重度的副作用。基因治疗是肿瘤治疗的一种新方法。一般而言，病毒载体和特别是腺病毒（Ad）载体是有效的天然基因递送系统，并且是癌症基因治疗的明显选择之一。临床和临床前研究发现，各种各样的方法，如肿瘤抑制和自杀基因治疗，肿瘤溶解，免疫治疗，抗血管生成和RNA干扰使用Ad载体已经相当有前途，但仍然有许多障碍需要克服。免疫原性增加、人群中预先存在的抗Ad免疫的流行以及缺乏特异性靶向限制了Ad载体的临床用途。近年来，已经进行了广泛的研究努力，以克服这些限制，通过各种方法，包括使用条件复制的Ad和特异性靶向肿瘤细胞。在这篇综述中，我们讨论了Ad载体用于癌症治疗的潜在优势和局限性。
Definitive treatment of cancer has eluded scientists for decades. Current therapeutic modalities like surgery, chemotherapy, radiotherapy and receptor-targeted antibodies have varied degree of success and generally have moderate to severe side effects. Gene therapy is one of the novel and promising approaches for therapeutic intervention of cancer. Viral vectors in general and adenoviral (Ad) vectors in particular are efficient natural gene delivery systems and are one of the obvious choices for cancer gene therapy. Clinical and preclinical findings with a wide variety of approaches like tumor suppressor and suicide gene therapy, oncolysis, immunotherapy, anti-angiogenesis and RNA interference using Ad vectors have been quite promising, but there are still many hurdles to overcome. Shortcomings like increased immunogenicity, prevalence of preexisting anti-Ad immunity in human population and lack of specific targeting limit the clinical usefulness of Ad vectors. In recent years, extensive research efforts have been made to overcome these limitations through a variety of approaches including the use of conditionally-replicating Ad and specific targeting of tumor cells. In this review, we discuss the potential strengths and limitations of Ad vectors for cancer therapy.